
USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$833.24M
Market Cap
-
P/E Ratio
-0.69
EPS
$3.80
52 Week High
$0.76
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $115M |
| Total Revenue | $115M |
| Cost Of Revenue | $4.2M |
| Costof Goods And Services Sold | $4.2M |
| Operating Income | -$60M |
| Selling General And Administrative | $36M |
| Research And Development | $138M |
| Operating Expenses | $175M |
| Investment Income Net | - |
| Net Interest Income | -$9.7M |
| Interest Income | $1.8M |
| Interest Expense | $12M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4.2M |
| Income Before Tax | -$56M |
| Income Tax Expense | $893K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$57M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$44M |
| Ebitda | -$40M |
| Net Income | -$57M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $115M |
| Total Revenue | $115M |
| Cost Of Revenue | $4.2M |
| Costof Goods And Services Sold | $4.2M |
| Operating Income | -$60M |
| Selling General And Administrative | $36M |
| Research And Development | $138M |
| Operating Expenses | $175M |
| Investment Income Net | - |
| Net Interest Income | -$9.7M |
| Interest Income | $1.8M |
| Interest Expense | $12M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4.2M |
| Income Before Tax | -$56M |
| Income Tax Expense | $893K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$57M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$44M |
| Ebitda | -$40M |
| Net Income | -$57M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Gossamer Bio, Inc. is a San Diego-based clinical-stage biopharmaceutical firm focused on the discovery and development of innovative therapies for immunology, inflammation, and oncology. With a robust pipeline that employs advanced scientific insights, Gossamer Bio addresses significant unmet medical needs through its diverse range of drug candidates. As it progresses through clinical trials, the company is committed to providing transformative treatment options for patients with complex diseases, establishing itself as an influential player in the biopharmaceutical sector.